Clinical Trial

DORA and LP in Alzheimer's Disease Biomarkers

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.
Protocol Amendment History 1 change
notable Sponsor changed: Washington University School of Medicine -> University of Minnesota 2026-07-14
Trial Details
NCT Number NCT06274528
Lead Sponsor University of Minnesota
Collaborators: National Institutes of Health (NIH), Eisai Inc., National Institute on Aging (NIA)
Conditions Alzheimer Disease
Enrollment 201 participants
Start Date 2024-03-11
Primary Completion 2030-03-31 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-13